Keyword: NGM Biopharmaceuticals
Expectations for NASH are still sky-high—some see billions for any drug that gets it right at peak—but the reality of clinical trials has been murky.
NGM presented data showing that its once-monthly nonalcoholic steatohepatitis drug improved insulin sensitivity in people with diabetes.
Fatty liver disease biotech NGM Bio has got off a $107 million IPO, following in the footsteps of rival GenFit.
NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.
The agreement gives Merck control of a drug designed to reduce liver fat content by selectively activating FGFR1c.
Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech looks to get into the mix with its big biopharma rivals for a blockbuster market.